Security
Revolution Medicines, Inc. Warrant · RVMDW
RVMDWNASDAQWarrantCurrentCIK 1628171Updated Oct 3, 2026
RVMDW price & chart
Loading TradingView…
NASDAQ:RVMDW on TradingView ↗About the company
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. These product candidates are investigational and have not been approved for commercial use in any indication. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,354,508,000Source | 2,558,301,000Source | 2,061,705,000Source | 811,930,000Source |
| Property, Plant and Equipment, NetUSD | 33,194,000Source | 24,289,000Source | 22,865,000Source | 18,659,000Source |
| GoodwillUSD | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 55,800,000Source | 56,670,000Source | 57,739,000Source | 58,807,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 383,745,000Source | 543,064,000Source | 696,148,000Source | 161,412,000Source |
| Assets, CurrentUSD | 2,075,037,000Source | 2,327,632,000Source | 1,879,281,000Source | 660,185,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 49,358,000Source | 38,333,000Source | 25,072,000Source | 10,569,000Source |
| Operating Lease, Right-of-Use AssetUSD | 132,084,000Source | 117,534,000Source | 77,149,000Source | 55,077,000Source |
| Other Assets, NoncurrentUSD | 14,779,000Source | 13,870,000Source | 7,032,000Source | 2,857,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 723,211,000Source | 293,097,000Source | 235,511,000Source | 126,742,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 19,000Source | 18,000Source | 16,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,869,102,000Source | -1,737,801,000Source | -1,137,708,000Source | -701,341,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 3,237,000Source | 1,321,000Source | 544,000Source | -1,780,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,631,297,000Source | 2,265,204,000Source | 1,826,194,000Source | 685,188,000Source |
| Additional Paid in Capital, Common StockUSD | 4,497,143,000Source | 4,001,666,000Source | 2,963,342,000Source | 1,388,300,000Source |
| Liabilities and EquityUSD | 2,354,508,000Source | 2,558,301,000Source | 2,061,705,000Source | 811,930,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 290,424,000Source | 163,914,000Source | 143,851,000Source | 61,984,000Source |
| Operating Lease, Liability, CurrentUSD | 16,468,000Source | 12,872,000Source | 7,369,000Source | 6,773,000Source |
| Accounts Payable, CurrentUSD | 64,616,000Source | 54,427,000Source | 61,788,000Source | 21,306,000Source |
| Operating Lease, Liability, NoncurrentUSD | 142,234,000Source | 122,971,000Source | 80,575,000Source | 57,432,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,353,000Source | 2,353,000Source | 3,115,000Source | 7,025,000Source |
| Other Liabilities, NoncurrentUSD | 1,208,000Source | 670,000Source | 1,458,000Source | 301,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,000,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 2,353,000Source | 2,353,000Source | 3,115,000Source | 7,025,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 3,972,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 118,389,000Source | 79,197,000Source | 61,772,000Source | 31,196,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | -1,254,000Source | -3,419,000Source | -1,256,000Source |
| Increase (Decrease) in Accounts PayableUSD | 9,535,000Source | -6,465,000Source | 32,469,000Source | 7,288,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | -738,000Source | -3,848,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -897,741,000Source | -557,436,000Source | -350,572,000Source | -224,401,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 118,058,000Source | -554,394,000Source | -342,598,000Source | -24,116,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 15,990,000Source | 10,308,000Source | 7,729,000Source | 10,816,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 0Source | 4,026,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 621,524,000Source | 959,413,000Source | 1,229,200,000Source | 301,432,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -158,159,000Source | -152,417,000Source | 536,030,000Source | 52,915,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 388,603,000Source | 546,762,000Source | 699,179,000Source | 163,149,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 118,389,000Source | 79,197,000Source | 61,772,000Source | 31,196,000Source |
| Amortization of Debt Issuance CostsUSD | 541,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | 870,000Source | 1,069,000Source | 1,068,000Source | 1,069,000Source |
| DepreciationUSD | 7,400,000Source | 6,200,000Source | 5,042,000Source | — |
| Depreciation, Amortization and Accretion, NetUSD | 7,780,000Source | 6,559,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -32,000Source | -118,000Source | -52,000Source | -19,000Source |
| General and Administrative ExpenseUSD | 195,037,000Source | 97,299,000Source | 75,621,000Source | 40,586,000Source |
| GoodwillUSD | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | -753,000Source | -3,524,000Source | -420,000Source |
| InterestExpenseNonoperatingUSD | 24,231,000Source | — | — | — |
| Investment Income, InterestUSD | 90,694,000Source | 86,883,000Source | 47,482,000Source | 9,154,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Nonoperating Income (Expense)USD | 51,068,000Source | 88,678,000Source | 47,294,000Source | 9,154,000Source |
| Operating ExpensesUSD | 1,182,369,000Source | 689,524,000Source | 498,765,000Source | 293,659,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 727,620,000Source | 323,706,000Source | 248,126,000Source |
| Proceeds from Stock Options ExercisedUSD | 21,134,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 11,580,000Source | 35,380,000Source |
| Operating Income (Loss)USD | -1,182,369,000Source | -689,524,000Source | -487,185,000Source | -258,279,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,131,301,000Source | -600,846,000Source | -439,891,000Source | -249,125,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -753,000Source | -3,524,000Source | -420,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Earnings Per Share, BasicUSD per share | -5.95Source | -3.58Source | -3.86Source | -3.08Source |
| Earnings Per Share, DilutedUSD per share | -5.95Source | -3.58Source | -3.86Source | -3.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 190,129,154Source | 167,737,672Source | 113,149,869Source | 80,626,525Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 190,129,154Source | 167,737,672Source | 113,149,869Source | 80,626,525Source |
| Interest Expense (non-operating)USD | 24,231,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 870,000Source | 1,069,000Source | 1,068,000Source | 1,069,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | -15,000Source | 324,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 5,000,000Source | 4,000,000Source |
| General and Administrative ExpenseUSD | 195,037,000Source | 97,299,000Source | 75,621,000Source | 40,586,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -1,131,301,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | 90,694,000Source | 86,883,000Source | 47,482,000Source | 9,154,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Nonoperating Income (Expense)USD | 51,068,000Source | 88,678,000Source | 47,294,000Source | 9,154,000Source |
| Operating ExpensesUSD | 1,182,369,000Source | 689,524,000Source | 498,765,000Source | 293,659,000Source |
| Research and Development ExpenseUSD | 987,332,000Source | 592,225,000Source | 423,144,000Source | 253,073,000Source |
Filing attachments
rvmd-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress · U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results · Rapidly implemented U.S. Expanded Access Program for eligible patients with previously treated metastatic pancreatic cancer · Achieved U.S. commercial launch rea…
Read attachment ↗rvmd-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress · Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation · RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administrati…
Read attachment ↗d19920dex41.htm · 8-K · 2026-04-17
EX-4.1 3 d19920dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 REVOLUTION MEDICINES, INC. INDENTURE Dated as of April 17, 2026 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. …
Read attachment ↗d19920dex42.htm · 8-K · 2026-04-17
EX-4.2 4 d19920dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 REVOLUTION MEDICINES, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of April 17, 2026 0.50% Convertible Senior Notes due 2033 CROSS REFERENCE TABLE* Trust Indenture Indenture Section Act Section 310 (a)(1) 10.09 (a)(2) 10.09 (a)(3) N/A (a)(4) …
Read attachment ↗